Drug Trial Radar · NCT05183646
A Study of the Efficacy and Safety of DMX-200 in Patients With FSGS Who Are Receiving an ARB
Last checked: Nov 19, 2026Latest source record: Feb 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
286
Planned (sponsor's estimate)
Start
May 30, 2022
Primary completion
Dec 2029
Study completion Dec 2029
Sponsor
- Lead sponsor
- Dimerix Bioscience Pty LtdIndustry
- Sponsor type
- Industry
- First posted
- Jan 10, 2022
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 12 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
DMX-200 (repagermanium) is a C-C chemokine receptor type 2 (CCR2) inhibitor that, when administered concurrently with an ARB, is designed to inhibit recruitment of monocytes implicated in the inflammatory chemokine environment of chronic disease. The purpose of this pivotal randomized double-blind study is to investigate the efficacy and safety of DMX-200 120 mg twice daily (BID) compared with placebo over a treatment period of 104 weeks in adult patients with FSGS who are being treated with an ARB. Given the rarity of the disease and the similarities between adults and pediatric patients with FSGS, Dimerix will also investigate the efficacy and safety of DMX 200 in adolescents aged 12 to 17 years. The double-blind period will be followed by an open-label extension (OLE) which aims to assess the long-term efficacy and safety of DMX 200 for up to 2 additional years.
Conditions
- FSGS
Interventions
DMX-200Drug
DMX-200 (repagermanium) is a C-C chemokine receptor type 2 (CCR2) inhibitor.
PlaceboDrug
Patients will receive 120 mg capsules of Placebo twice daily
Primary outcomes
What the sponsor says the trial is designed to measure.
- Evaluate the efficacy of DMX-200 in terms of urine protein/creatinine ratio (PCR) in patients with FSGS who are receiving an ARB.Time frame: Baseline to Week 35
- Evaluate the efficacy of DMX-200 in terms of estimated glomerular filtration rate (eGFR) slope in patients with FSGS who are receiving an ARB (Analysis at week 35 and Week 104).Time frame: Baseline to Week 104
- OLE - Assess the long-term safety and tolerability of open-label treatment with DMX-200 in patients with FSGS who are receiving an ARB.Time frame: Double-blind baseline to Week 216
Locations
220 sites in 21 countries. Site status is shown where the registry gives one.
University of Alabama at Birmingham
Birmingham, Alabama · Active not recruiting
Phoenix Children's Hospital
Phoenix, Arizona · Recruiting
Arizona Kidney Disease and Hypertension Center
Phoenix, Arizona · Active not recruiting
Loma Linda University Medical Center
Loma Linda, California · Active not recruiting
Cedars-Sinai Medical Center
Los Angeles, California · Recruiting
University of California, Los Angeles
Los Angeles, California · Recruiting
Amicis Research Centre
Northridge, California · Active not recruiting
Northridge Clinical Research Inc.
Northridge, California · Active not recruiting
Kaiser Permanente
Oakland, California · Recruiting
University of California Davis Health System
Sacramento, California · Recruiting
Scripps Health
San Diego, California · Active not recruiting
Stanford Hospital and Clinic
Stanford, California · Recruiting
University of Colorado Anschutz Medical Campus
Denver, Colorado · Recruiting
Denver Nephrology Research Division
Denver, Colorado · Recruiting
South Florida Nephrology Group, P.A.
Coral Springs, Florida · Active not recruiting
Nicklaus Children's Hospital
Miami, Florida · Recruiting
CTR Oakwater LLC
Orlando, Florida · Recruiting
Emory University School of Medicine
Atlanta, Georgia · Recruiting
Georgia Nephrology
Lawrenceville, Georgia · Active not recruiting
Boise Kidney
Boise, Idaho · Active not recruiting
CARE Institute - Idaho Falls
Idaho Falls, Idaho · Active not recruiting
University of Chicago
Chicago, Illinois · Active not recruiting
NorthShore University HealthSystem
Evanston, Illinois · Active not recruiting
Nephrology Associates of Northern Illinois and Indiana (NANI Research)
Oak Brook, Illinois · Active not recruiting
University of Louisville
Louisville, Kentucky · Active not recruiting
The Johns Hopkins Hospital
Baltimore, Maryland · Active not recruiting
University of Michigan
Ann Arbor, Michigan · Recruiting
Intermed Consultants
Edina, Minnesota · Active not recruiting
University of Minnesota
Minneapolis, Minnesota · Recruiting
CARE Institute - Nephrology & Hypertension Associates
Tupelo, Mississippi · Active not recruiting
Children's Mercy Research Institute
Kansas City, Missouri · Recruiting
Washington University, School of Medicine
St Louis, Missouri · Recruiting
Somnos Clinical Research
Lincoln, Nebraska · Active not recruiting
Hackensack University Medical Center
Hackensack, New Jersey · Recruiting
Renal Medicine Associates
Albuquerque, New Mexico · Active not recruiting
Icahn School of Medicine at Mount Sinai
New York, New York · Recruiting
University of North Carolina
Chapel Hill, North Carolina · Recruiting
Atrium Health
Charlotte, North Carolina · Recruiting
University Hospitals Cleveland Medical Center
Cleveland, Ohio · Active not recruiting
Cleveland Clinic
Cleveland, Ohio · Active not recruiting
Showing 40 of 220 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.